Literature DB >> 19249570

Treatment of nonalbumin rats by transplantation of immortalized hepatocytes using artificial human chromosome.

M Ito1, M Ikeno, H Nagata, T Yamamoto, A Hiroguchi, I J Fox, S Miyakawa.   

Abstract

The shortage of organ donors has impeded the development of human hepatocyte transplantation. Immortalized hepatocytes, however, could provide an unlimited supply of transplantable cells. To determine whether immortalized hepatocytes could provide global metabolic support in end-stage liver disease, rat hepatocyte clones were developed by transduction with the gene encoding the simian virus 40 T antigen (SVLT) using the new technique of human artificial mini chromosome (HAC). Immortalized rat hepatocyte clones were developed by transduction with the gene encoding the SV40 using HAC. Many clones were obtained using this technique. From comparison of the properties of all these clones using the normal hepatocytes and reverse transcription-polymerase chain reaction (RT-PCR), the characteristics of the cell clones (at least partially characterized, and assayed for albumin, glucose-6-phosphate and dipeptidyl peptidase-4, gamma-glutamyltranspeptidase, SVLT and beta-actin expression by RT-PCR) showed no differences other than the immortalization. We compared the albumin bands of the first-day (0-day) and 30-day cells by RT-PCR, showing conditions to be stable for at least 1 month. Three experimental animal model groups were used for albumin analysis: nonalbumin rats with 2/3 hepatectomy only (R-NARs; n = 4); R-NARs with intrasplenic transplantation of 3 x 10(7) primary hepatocytes (pHTx; n = 4); and R-NARs with intrasplenic transplantation of 3 x 10(7) immortalized hepatocytes (iHTx; n = 4). All HTx groups produced albumin, but the immortalized hepatocyte group did not generate significantly elevated albumin levels compared with primary hepatocytes. The results presented herein have demonstrated an initial step toward the development of immortalized hepatocytes for transplantable cells or artificial organs using HAC technology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19249570     DOI: 10.1016/j.transproceed.2008.10.023

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  9 in total

Review 1.  Human artificial chromosomes for gene delivery and the development of animal models.

Authors:  Yasuhiro Kazuki; Mitsuo Oshimura
Journal:  Mol Ther       Date:  2011-07-12       Impact factor: 11.454

Review 2.  A new generation of human artificial chromosomes for functional genomics and gene therapy.

Authors:  Natalay Kouprina; William C Earnshaw; Hiroshi Masumoto; Vladimir Larionov
Journal:  Cell Mol Life Sci       Date:  2012-08-21       Impact factor: 9.261

3.  Immortalized Human Hepatic Cell Lines for In Vitro Testing and Research Purposes.

Authors:  Eva Ramboer; Tamara Vanhaecke; Vera Rogiers; Mathieu Vinken
Journal:  Methods Mol Biol       Date:  2015

4.  Generation of a conditionally self-eliminating HAC gene delivery vector through incorporation of a tTAVP64 expression cassette.

Authors:  Artem V Kononenko; Nicholas C O Lee; Mikhail Liskovykh; Hiroshi Masumoto; William C Earnshaw; Vladimir Larionov; Natalay Kouprina
Journal:  Nucleic Acids Res       Date:  2015-02-20       Impact factor: 16.971

Review 5.  A pathway from chromosome transfer to engineering resulting in human and mouse artificial chromosomes for a variety of applications to bio-medical challenges.

Authors:  Mitsuo Oshimura; Narumi Uno; Yasuhiro Kazuki; Motonobu Katoh; Toshiaki Inoue
Journal:  Chromosome Res       Date:  2015-02       Impact factor: 5.239

6.  Re-engineering an alphoid(tetO)-HAC-based vector to enable high-throughput analyses of gene function.

Authors:  Artem V Kononenko; Nicholas C O Lee; William C Earnshaw; Natalay Kouprina; Vladimir Larionov
Journal:  Nucleic Acids Res       Date:  2013-04-04       Impact factor: 16.971

7.  Human AlphoidtetO Artificial Chromosome as a Gene Therapy Vector for the Developing Hemophilia A Model in Mice.

Authors:  Sergey V Ponomartsev; Sergey A Sinenko; Elena V Skvortsova; Mikhail A Liskovykh; Ivan N Voropaev; Maria M Savina; Andrey A Kuzmin; Elena Yu Kuzmina; Alexandra M Kondrashkina; Vladimir Larionov; Natalay Kouprina; Alexey N Tomilin
Journal:  Cells       Date:  2020-04-03       Impact factor: 6.600

8.  Novel strategy for hepatocyte transplantation using resected organ with hepatocellular carcinoma or cholangiocarcinoma after hepatectomy.

Authors:  Toki Kawai; Masahiro Ito; Chihiro Hayashi; Naoki Yamamoto; Yukio Asano; Satoshi Arakawa; Akihiko Horiguchi
Journal:  Fujita Med J       Date:  2019-11-02

Review 9.  Strategies for immortalization of primary hepatocytes.

Authors:  Eva Ramboer; Bram De Craene; Joery De Kock; Tamara Vanhaecke; Geert Berx; Vera Rogiers; Mathieu Vinken
Journal:  J Hepatol       Date:  2014-06-06       Impact factor: 25.083

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.